Investigators at the MD Anderson Cancer Center have proposed a different strategy, based on an initial phase with biological agents alone (RLI: rituximab, lenalidomide, and ibrutinib) administered for two cycles to patients with non-GCB DLBCL, followed by the addition of conventional chemotherapy (either R-CHOP or R-EPOCH). The gene discussed is DDIT3; the disease is diffuse large B-cell lymphoma.